CORT icon

Corcept Therapeutics

67.54 USD
-0.47
0.69%
At close Feb 10, 4:00 PM EST
After hours
67.50
-0.04
0.06%
1 day
-0.69%
5 days
2.38%
1 month
35.49%
3 months
14.36%
6 months
98.01%
Year to date
35.16%
1 year
182.00%
5 years
381.05%
10 years
2,064.74%
 

About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Employees: 352

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

125% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 28

63% more call options, than puts

Call options by funds: $54.3M | Put options by funds: $33.3M

40% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 7 (+2) [Q3]

37% more capital invested

Capital invested by funds: $2.95B [Q2] → $4.04B (+$1.1B) [Q3]

11% more funds holding

Funds holding: 284 [Q2] → 315 (+31) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 104

3.53% less ownership

Funds ownership: 87.17% [Q2] → 83.64% (-3.53%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$80
18%
upside
Avg. target
$105
55%
upside
High target
$130
92%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
37% 1-year accuracy
71 / 192 met price target
18%upside
$80
Buy
Reiterated
7 Feb 2025
Canaccord Genuity
Edward Nash
65% 1-year accuracy
13 / 20 met price target
92%upside
$130
Buy
Maintained
30 Jan 2025

Financial journalist opinion

Based on 11 articles about CORT published over the past 30 days

Positive
Zacks Investment Research
1 week ago
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?
Corcept (CORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?
Neutral
Zacks Investment Research
1 week ago
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Positive
Zacks Investment Research
1 week ago
All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy
Positive
FXEmpire
1 week ago
Big Money Keeps Buying Corcept
Corcept Therapeutics Incorporated (CORT) shares rise on treatment advances, Big Money buys.
Big Money Keeps Buying Corcept
Positive
Zacks Investment Research
1 week ago
Buy These 5 Stocks With Recent Price Strength Amid a Volatile January
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are OPFI, CORT, DXPE, PPTA, GHM.
Buy These 5 Stocks With Recent Price Strength Amid a Volatile January
Positive
Zacks Investment Research
2 weeks ago
Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"
Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market.
Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"
Neutral
PRNewsWire
2 weeks ago
Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm
NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Inc. (NASDAQ: CORT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm
Positive
Zacks Investment Research
2 weeks ago
Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?
Positive
Seeking Alpha
2 weeks ago
Corcept Therapeutics Generating Strong Revenue And Profit Growth
Corcept's sole drug, Korlym, treats Cushing Syndrome, a more prevalent condition than previously known, driving strong revenue and profit growth. A new market for Corcept's medications, diabetics, is poised to take the company to the next level. Long-term goal is $3 billion revenue by 2029, driven by the new drug Relacorilant, which could expand market reach beyond Korlym.
Corcept Therapeutics Generating Strong Revenue And Profit Growth
Positive
Investors Business Daily
2 weeks ago
Medical Stock Soars To Highs As Cortisol Screening Grows
Corcept Therapeutics makes drugs that modulate cortisol. The post Medical Stock Soars To Highs As Cortisol Screening Grows appeared first on Investor's Business Daily.
Medical Stock Soars To Highs As Cortisol Screening Grows
Charts implemented using Lightweight Charts™